Overview

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Status:
Active, not recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a clinical trial that will compare survival and sickle related outcomes in adolescents and young adults with severe sickle cell disease after bone marrow transplantation and standard of care. The primary outcome is 2-year overall survival.

Phase:

Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Collaborators:

Blood and Marrow Transplant Clinical Trials Network
Dana-Farber Cancer Institute
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
National Marrow Donor Program

Treatments:

Alemtuzumab
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Lenograstim
Melphalan
Methotrexate
Sirolimus
Tacrolimus
Thymoglobulin